Amylyx Pharmaceuticals
AMLX
95 hedge funds and large institutions have $1.05B invested in Amylyx Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 16 closing their positions.
106% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 16
104% more capital invested
Capital invested by funds: $513M → $1.05B (+$532M)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
58% more call options, than puts
Call options by funds: $94.4M | Put options by funds: $59.8M
22% more funds holding
Funds holding: 78 → 95 (+17)
18.19% more ownership
Funds ownership: 45.48% → 63.67% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$48.2M |
| 3 |
BlackRock
New York
|
+$39.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$33.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$34.9M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$23.1M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$15.9M |
| 4 |
TCM
Tybourne Capital Management
Hong Kong
|
-$14.8M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$14.2M |
AMLX Hedge Fund Activity: Q3 2022 in Review
95 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q3 2022, worth a combined $1.05B — up 104% from $513M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AMLX positions and 16 closed out — a net gain of 17 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $62.9M. The largest seller was Viking Global Investors, cutting an estimated $34.9M.
- 95 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q3 2022, up from 78 in Q2 2022.
- Funds reported $1.05B of Amylyx Pharmaceuticals stock for Q3 2022, up 104% quarter-over-quarter.
- 33 funds opened new Amylyx Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of +17 holders.
- The largest Amylyx Pharmaceuticals buyer in Q3 2022 was Vanguard Group, an estimated $62.9M added.
- The largest Amylyx Pharmaceuticals seller in Q3 2022 was Viking Global Investors, an estimated $34.9M sold.
Based on aggregated 13F filings for Q3 2022.